[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351534-105":59,"doc-detail-351534-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","tumor-agnostic-landscape-with-her2-amplification-in-japan-real-world-prevalence-and-implications-for-targeting-her2","Tumor-Agnostic Landscape with HER2 Amplification in Japan - Real-World Prevalence and Implications for Targeting HER2","","Limited data exist on ERBB2/HER2 amplification prevalence across all solid tumors. This retrospective observational study (UMIN000057382) analyzed 89,374 eligible Japanese patients using comprehensive genomic profiling data from the Center for Cancer Genomics and Advanced Therapeutics database. HER2 amplification was detected in 5,119 patients (5.7%), with highest rates in esophagus/stomach tumors (12.9%) and bladder/urinary tract tumors (10.6%). FoundationOne CDx showed the highest detection rate (7.4%) versus other platforms. Results support expanding HER2 evaluation beyond conventional tumor types for potential HER2-targeted therapy, including trastuzumab deruxtecan, in Japan.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tumor-agnostic-landscape-with-her2-amplification-in-japan-real-world-prevalence-and-implications-for-targeting-her2/351534/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tumor-agnostic-landscape-with-her2-amplification-in-japan-real-world-prevalence-and-implications-for-targeting-her2/351534.png","ImageObject",300,407,{"name":92,"@type":93},"วิน","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",18,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main goal of the study in Japan?","Question",{"text":113,"@type":114},"To clarify the real-world prevalence of ERBB2/HER2 amplification across all types of solid tumors in Japan and derive implications for HER2-targeted treatment strategies.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How many patients were analyzed, and what proportion had HER2 amplification?",{"text":118,"@type":114},"The study analyzed 89,374 eligible patients with solid tumors; 5,119 patients had HER2 amplification, representing 5.7%.",{"name":120,"@type":111,"acceptedAnswer":121},"Which tumors showed the highest HER2 amplification rates?",{"text":122,"@type":114},"The highest rates were observed in esophagus/stomach tumors (12.9%), followed by bladder/urinary tract tumors (10.6%), then breast (9.5%), biliary tract (8.4%), and uterus (8.4%).",{"name":124,"@type":111,"acceptedAnswer":125},"Did assay platform choice affect HER2 amplification detection?",{"text":126,"@type":114},"Yes. Among five platforms, FoundationOne CDx accounted for most CGP tests (69.7%) and had the highest detection rate (7.4%), while other platforms showed lower detection rates (range 1.9–15.4% of all tests; 1.5–2.3% detection rates).","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},351534,1790465274,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":150,"preview_page_count":19,"preview_urls":151},2336475104736,"https://ap-avatar.wpscdn.com/avatar/22000c4c5e0e5b17e70?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786591360781797222","Article  \nTumor-Agnostic Landscape with HER2 Amplification in Japan: Real-World Prevalence and Implications for Targeting HER2  \nYutaka Hatanaka 1, *, Jun Sasano 2 and Osamu Takizawa 3  \nReceived: 13 February 2026  \nRevised: 26 March 2026  \nAccepted: 28 March 2026  \nPublished: 30 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Center for Development of Advanced Diagnostics, Hokkaido University Hospital, Sapporo, Hokkaido 060-8648, Japan  \n2 Oncology Medical Science Department, Daiichi Sankyo Co., Ltd., Chuo-ku, Tokyo 103-8426, Japan  \n3 Data Intelligence Department, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo 140-0005, Japan  \n* [Correspondence: yhatanaka@huhp.hokudai.ac.jp](Correspondence: yhatanaka@huhp.hokudai.ac.jp); Tel.: +81-11-706-7933  \nSimple Summary  \nConsidering the availability of human epidermal growth factor receptor 2 (ERBB2/HER2)-targeting therapy, the status of HER2 amplification in patients with all types of solid tumors needs to be clarified. We analyzed 89,374 eligible patients with solid tumors using comprehensive genomic profiling data from Japanese nationwide database, and HER2 amplification was detected in 5119 patients (5.7%): highest rates of HER2 amplification were observed in patients with tumors of the esophagus/stomach (12.9%), followed by tumors of the bladder/urinary tract (10.6%), breast (9.5%), biliary tract (8.4%), and uterus (8.4%) . The detection of HER2 amplification was highest with FoundationOne CDx assay platform (7.4%) compared to other platforms. We report that HER2 amplification occurs in several tumors, including rare tumors, and is not limited to conventional tumor types. The results suggest that there is a need to expand the evaluation of HER2 amplification and consequently HER2-targeting therapy such as trastuzumab deruxtecan in Japan.  \nAbstract  \nLimited data exist on the prevalence of human epidermal growth factor receptor 2 (ERBB2 /HER2) amplification in patients with all types of solid tumors. This retrospective, observational study (UMIN ID: UMIN000057382) analyzed the prevalence of HER2 amplification across all solid tumors using comprehensive genomic profiling (CGP) data from the Center for Cancer Genomics and Advanced Therapeutics database in Japan. We analyzed 89,374 eligible patients with solid tumors: HER2 amplification was detected in 5119 patients (5.7%) . The highest rates of HER2 amplification were observed in patients with tumors of the esophagus/stomach (12.9%), followed by tumors of the bladder/urinary tract (10.6%), breast (9.5%), biliary tract (8.4%), and uterus (8.4%) . Among the five assay platforms, FoundationOne CDx accounted for 69.7% of all CGP tests and had an HER2 amplification detection rate of 7.4%, compared to the other four platforms (range: 1.9–15.4% of all CGP tests [detection rates: 1.5–2.3%]) . Substantial differences were observed in the mutation frequencies of multiple genes between HER2 amplified and HER2 non-amplified tumors. The results highlight that HER2 amplification extends beyond conventional tumor types and enables the identification, via CGP testing, of non-traditional tumor subsets (cancers other than breast and gastric cancer), including rare cancers, that could be candidates for HER2-targeting therapy such as trastuzumab deruxtecan in Japan.  \nKeywords: comprehensive genomic profiling; human epidermal growth factor receptor 2 amplification; next-generation sequencing; prevalence; solid tumors  \n1. Introduction  \nHuman epidermal growth factor receptor 2 (HER2, also known as ERBB2) is a protooncogene that encodes a transmembrane tyrosine kinase receptor involved in the regulation of cell growth, differentiation, and survival [1] . HER2-positive tumors are identified by either protein overexpression (using immunohistochemistry with a score of 3+ [IHC 3+], whic","cbCaikPAMCPwbPdm","https://ap.wps.com/l/cbCaikPAMCPwbPdm","pdf",3939496,17,"English","# Simple Summary\n# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"What was the main goal of the study in Japan?\",\"answer\":\"To clarify the real-world prevalence of ERBB2/HER2 amplification across all types of solid tumors in Japan and derive implications for HER2-targeted treatment strategies.\"},{\"question\":\"How many patients were analyzed, and what proportion had HER2 amplification?\",\"answer\":\"The study analyzed 89,374 eligible patients with solid tumors; 5,119 patients had HER2 amplification, representing 5.7%.\"},{\"question\":\"Which tumors showed the highest HER2 amplification rates?\",\"answer\":\"The highest rates were observed in esophagus/stomach tumors (12.9%), followed by bladder/urinary tract tumors (10.6%), then breast (9.5%), biliary tract (8.4%), and uterus (8.4%).\"},{\"question\":\"Did assay platform choice affect HER2 amplification detection?\",\"answer\":\"Yes. Among five platforms, FoundationOne CDx accounted for most CGP tests (69.7%) and had the highest detection rate (7.4%), while other platforms showed lower detection rates (range 1.9–15.4% of all tests; 1.5–2.3% detection rates).\"}]","Tumor-Agnostic Landscape with HER2 Amplification in Japan - Real-World Prevalence and Implications for Targeting HER2 | PDF",1790094618,43,[152,156,160,164],{"page_no":8,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d043c0d28e3407cbc795c5156f21f7d3.webp",983,1390,{"page_no":14,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11749a14ac99d4a5faea71e774e71089.webp",982,1388,{"page_no":81,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de1d951f1a8b25c4fe17d1e722c6a983.webp",981,1387,{"page_no":19,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ee54e9300dcd02467153947dc24437d.webp",980,1385]